2018
Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia
Sullivan R, Abraham A, Simpson C, Olear E, Carpenter T, Deng Y, Chen C, Insogna KL. Three-Month Randomized Clinical Trial of Nasal Calcitonin in Adults with X-linked Hypophosphatemia. Calcified Tissue International 2018, 102: 666-670. PMID: 29383408, PMCID: PMC5957766, DOI: 10.1007/s00223-017-0382-0.Peer-Reviewed Original ResearchConceptsLevels of FGF23Nasal salmon calcitoninSalmon calcitoninStudy drugVisit 2Day 2Levels of PTHPrincipal outcome variableTmP/GFRSingle subcutaneous dosePlacebo nasal sprayNasal calcitoninSerum calciumSubcutaneous doseVisit 4Dihydroxyvitamin DSerum phosphorusVisit 3Final doseVisit 1Nasal sprayClinical trialsSerial measurementsDrug doseFGF23 production
2015
Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia
Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey J, Glorieux FH, Portale AA, Insogna K, Carpenter TO, Peacock M. Pharmacokinetics and pharmacodynamics of a human monoclonal anti‐FGF23 antibody (KRN23) in the first multiple ascending‐dose trial treating adults with X‐linked hypophosphatemia. The Journal Of Clinical Pharmacology 2015, 56: 176-185. PMID: 26073451, PMCID: PMC5042055, DOI: 10.1002/jcph.570.Peer-Reviewed Original ResearchConceptsConcentration-time curveSerum fibroblast growth factor 23Multiple ascending dose trialFibroblast growth factor 23Ascending dose trialHuman IgG1 monoclonal antibodyLow-normal serumRecombinant human IgG1 monoclonal antibodyDihydroxyvitamin D concentrationsGlomerular filtration rateGrowth factor 23Serum inorganic phosphorusSerum Pi concentrationIgG1 monoclonal antibodyFGF23 antibodyDose adjustmentFactor 23Serum PiFiltration ratePhosphate reabsorptionBone markersKRN23D concentrationsNormal serumMonoclonal antibodiesProlonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23
Imel EA, Zhang X, Ruppe MD, Weber TJ, Klausner MA, Ito T, Vergeire M, Humphrey JS, Glorieux FH, Portale AA, Insogna K, Peacock M, Carpenter TO. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 2565-2573. PMID: 25919461, PMCID: PMC4495171, DOI: 10.1210/jc.2015-1551.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugDrug Administration ScheduleFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsGlomerular Filtration RateHumansImmunoglobulin GMaleMiddle AgedPhosphorusRecombinant ProteinsTreatment OutcomeYoung AdultConceptsTmP/GFRSerum PiNormal rangeOpen-label phase 1/2 studyElevated fibroblast growth factor 23Fibroblast growth factor 23Phase 1/2 studyDose-escalation studyGlomerular filtration ratePre-dose levelsGrowth factor 23Favorable safety profileMain outcome measuresProportion of subjectsAcademic medical centerPeak PiSerum inorganic phosphorusPg/mLUrinary calciumDose escalationFactor 23Monthly dosesSerum phosphorusDihydroxyvitamin DSafety profile
2014
Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study
Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, Gundberg CM, Insogna KL. Effect of Paricalcitol on Circulating Parathyroid Hormone in X-Linked Hypophosphatemia: A Randomized, Double-Blind, Placebo-Controlled Study. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: 3103-3111. PMID: 25029424, PMCID: PMC4154090, DOI: 10.1210/jc.2014-2017.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAlkaline PhosphataseBone Density Conservation AgentsChildDouble-Blind MethodErgocalciferolsFamilial Hypophosphatemic RicketsFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansHyperparathyroidismMaleMiddle AgedParathyroid HormonePhosphorusPlacebosProspective StudiesTreatment OutcomeVitamin DYoung AdultConceptsRenal phosphate thresholdGlomerular filtration rateBone scanSerum phosphorusFiltration rateXLH patientsEffect of paricalcitolUse of paricalcitolPlacebo-treated subjectsElevated PTH levelsSerum calcium levelsSuppression of PTHHospital research unitSerum alkaline phosphatase activityPTH levelsCreatinine levelsSecondary outcomesStandard therapyUrinary calciumPlacebo subjectsParathyroid hormoneSerum calciumAlkaline phosphatase activityD levelsSkeletal improvement
2011
Calcitonin Administration in X-Linked Hypophosphatemia
Liu ES, Carpenter TO, Gundberg CM, Simpson CA, Insogna KL. Calcitonin Administration in X-Linked Hypophosphatemia. New England Journal Of Medicine 2011, 364: 1678-1680. PMID: 21524226, PMCID: PMC3162370, DOI: 10.1056/nejmc1010928.Peer-Reviewed Original Research
1998
Dietary protein affects intestinal calcium absorption 1 , 2 – 3
Kerstetter JE, O'Brien KO, Insogna KL. Dietary protein affects intestinal calcium absorption 1 , 2 – 3. American Journal Of Clinical Nutrition 1998, 68: 859-865. PMID: 9771863, DOI: 10.1093/ajcn/68.4.859.Peer-Reviewed Original ResearchConceptsFractional calcium absorptionLow-protein dietUrinary calcium excretionCalcium absorptionDay 4Calcium excretionSecondary hyperparathyroidismDietary proteinDual-stable calcium isotopesGlomerular filtration rateIntestinal calcium absorptionHigh-protein dietCalcitropic hormonesCalcium metabolismAdditional womenFiltration rateIntestinal absorptionDay 5Young womenRandom orderDietHyperparathyroidismExperimental dietsDietary fiberExcretion
1988
Humoral Hypercalcemia of Malignancy in Canine Lymphosarcoma*
Weir EC, Norrdin RW, Matus RE, Brooks MB, Broadus AE, Mitnick M, Johnston SD, Insogna KL. Humoral Hypercalcemia of Malignancy in Canine Lymphosarcoma*. Endocrinology 1988, 122: 602-608. PMID: 2828006, DOI: 10.1210/endo-122-2-602.Peer-Reviewed Original ResearchConceptsAdenylate cyclase-stimulating activityHypercalcemic dogsCanine lymphosarcomaFractional phosphorus excretionEvidence of tumorQuantitative bone histomorphometryBone-resorbing factorsImmunoreactive PTH levelsPathogenesis of hypercalcemiaIliac crest biopsiesTumor tissue extractsCyclase-stimulating activityBone histomorphometric findingsCalcium excretionPTH levelsHumoral hypercalcemiaDihydroxyvitamin DBone resorptionHistomorphometric findingsBone histomorphometryPTH receptorBiopsy siteCrest biopsiesTumor extractsCompensatory increase
1986
Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of Malignancy
GODSALL JW, BURTIS WJ, INSOGNA KL, BROADUS AE, STEWART AF. Nephrogenous Cyclic AMP, Adenylate Cyclase-Stimulating Activity, and the Humoral Hypercalcemia of Malignancy. 1986, 42: 705-750. PMID: 3016837, DOI: 10.1016/b978-0-12-571142-5.50021-5.BooksConceptsNephrogenous cyclic AMPCyclase-stimulating activityUcAMP excretionHumoral hypercalcemiaLocal osteolytic hypercalcemiaAdenylate cyclase-stimulating activityBone-resorbing activityCyclic AMPHPT groupNcAMP excretionNormocalcemic patientsPathophysiologic syndromeTumor extractsAnimal modelsHypercalcemiaAnimal tumorsTumorsNcAMPHHMExcretionPatientsMalignancyObserved elevationBasic proteinAMP
1985
Elevated Production Rate of 1,25-Dihydroxyvitamin D in Patients with Absorptive Hypercalciuria*
INSOGNA K, BROADUS A, DREYER B, ELLISON A, GERTNER J. Elevated Production Rate of 1,25-Dihydroxyvitamin D in Patients with Absorptive Hypercalciuria*. The Journal Of Clinical Endocrinology & Metabolism 1985, 61: 490-495. PMID: 2991323, DOI: 10.1210/jcem-61-3-490.Peer-Reviewed Original ResearchConceptsAbsorptive hypercalciuriaMicrograms/dayNormal subjectsMetabolic clearancePlasma radioactivityMean steady-state concentrationMCR valuesHypercalciuric patientsCalcium intakeDihydroxyvitamin DSerial measurementsHypercalciuriaPatientsConstant infusionConflicting resultsClearanceSteady-state concentrations
1983
Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets.
Insogna KL, Broadus AE, Gertner JM. Impaired phosphorus conservation and 1,25 dihydroxyvitamin D generation during phosphorus deprivation in familial hypophosphatemic rickets. Journal Of Clinical Investigation 1983, 71: 1562-1569. PMID: 6306051, PMCID: PMC370362, DOI: 10.1172/jci110912.Peer-Reviewed Original ResearchConceptsFamilial hypophosphatemic ricketsNormal subjectsHypophosphatemic ricketsImmunoreactive parathyroid hormone levelsD plasma levelsNephrogenous cyclic AMPParathyroid hormone levelsGlomerular filtration rateDietary phosphorus deprivationHealthy male volunteersTubular reabsorptive capacityLow phosphorus dietCyclic AMP measurementsMale patientsRenal responseFiltration ratePlasma levelsHormone levelsAbnormal responseMale volunteersReabsorptive capacityPatientsPhosphorus intakePhosphorus dietPhosphate conservation
1982
Influence of pregnancy on immunoreactive parathyroid hormone levels
Gillette M, Insogna K, Lewis A, Baran D. Influence of pregnancy on immunoreactive parathyroid hormone levels. Calcified Tissue International 1982, 34: 9-12. PMID: 6279256, DOI: 10.1007/bf02411200.Peer-Reviewed Original ResearchConceptsImmunoreactive PTHTubular maximum phosphate reabsorptionImmunoreactive parathyroid hormone levelsAge-matched female controlsHealthy pregnant patientsNephrogenous cAMP excretionParathyroid hormone metabolismHealthy age-matched female controlsParathyroid hormone levelsInfluence of pregnancySignificant increaseBiological effectsIPTH levelsPregnant patientsCreatinine clearanceUrinary calciumCreatinine ratioPTH metabolismSerum calciumSerum phosphorusThird trimesterVitamin DBlood levelsBone resorptionPhosphate reabsorption
1981
Effect of Age on Serum Immunoreactive Parathyroid Hormone and Its Biological Effects*
INSOGNA K, LEWIS A, LIPINSKI B, BRYANT C, BARAN D. Effect of Age on Serum Immunoreactive Parathyroid Hormone and Its Biological Effects*. The Journal Of Clinical Endocrinology & Metabolism 1981, 53: 1072-1075. PMID: 6270181, DOI: 10.1210/jcem-53-5-1072.Peer-Reviewed Original ResearchConceptsIPTH levelsElderly subjectsTubular maximum phosphate reabsorptionImmunoreactive parathyroid hormone levelsSerum immunoreactive parathyroid hormoneImmunoreactive parathyroid hormoneParathyroid hormone levelsBiological effectsCreatinine clearanceEffect of ageNephrogenous cAMPUrinary calciumCreatinine ratioSerum phosphateParathyroid hormoneBone lossCalcium ingestionBone resorptionPhosphate reabsorptionHormone levelsHealthy volunteersSignificant negative correlationSignificant positive correlationIPTHOlder volunteers